3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase 2
3
Phase 1
2
Phase 4
1
Phase 2/3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
106
Carcinoma, Intraductal, Noninfiltrating
6
Neoplasms
4
Neoplasm Metastasis
3
Breast Neoplasms, Male
3
Breast Diseases
3
Breast Carcinoma In Situ
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Sexual Dysfunction, Physiological
1
Seizures
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Lethal Congenital Contracture Syndrome 2
1
Inflammatory Breast Neoplasms
1
Hypogonadism
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Erectile Dysfunction
1
Epilepsy
1
Endometrial Stromal Tumors
1
ER+ Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasm Female
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
Anastrozole
×
Clear all
NCT02188745
2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2
Completed
19 enrolled
NCT02894398
2023-03-13
INGE-B
iOMEDICO AG
Phase 2
Completed
388 enrolled
NCT01151215
2014-07-25
MINT
AstraZeneca
Phase 2
Terminated
482 enrolled
10 charts